Celltrion: Understanding Inflectra's U.S. Challenges
Celltrion Inc (068270 KS) 's Inflectra (biosimilar of Remicade marketed in the U.S.) has struggled to gain a foothold in the market since its...
814 Views
Close Long/Short on Celltrion/Celltrion Healthcare: Market Mood on Placement Is Surprisingly Mild
Damage wasn't too harsh on Celltrion Healthcare (091990 KS). Both local institutions and foreign investors seem to have been much milder this time...
617 Views
Celltrion Healthcare Placement: Two Mitigating Factors, Short Healthcare But Long Celltrion
It is quite clear that Celltrion Healthcare (091990 KS) didn't do well in the previous placement (by Temasek) back on Mar 6. The price...
924 Views
Celltrion Healthcare Placement: Weigh Down from FDA Uncertainty and Placement Overhang
Celltrion Healthcare's shareholder, One Equity Partners, is selling USD 355 million of shares via a secondary placement today. This is the first...
684 Views
Another Negative Sign for Celltrion: Remsima Retail Price Is Falling Too Fast Too Much
Celltrion Healthcare (091990 KS) submitted its 1H18 semi-annual report yesterday. And with this semi-annual report, we finally got to know the...
926 Views